浦口新药中标国家集采

Core Viewpoint - The recent announcement of the 11th batch of national centralized procurement results highlights that Nanjing Fangsheng and its drug, Tangjing (Dapagliflozin Tablets), have successfully won the bid, showcasing the company's strength and enhancing its brand influence [1] Group 1: Company Overview - Dapagliflozin Tablets are SGLT-2 inhibitors primarily used for improving blood sugar control in adult patients with type 2 diabetes [1] - The drug was approved for entry into China in 2017, with its national patent set to expire in March 2028 [1] - Fangsheng Medicine has received approval for a total of 8 drug products, with multiple applications pending and over 20 pipelines in research, alongside nearly 50 authorized patents [1] Group 2: Market Impact - The successful bid in the national procurement reflects the company's capabilities and is expected to facilitate the entry of its drugs into more medical terminals across the country [1] - This achievement is anticipated to motivate the company to continue focusing on its mission of making quality medications more accessible to patients, further deepening its engagement in the biopharmaceutical field [1]